About UCSF Search UCSF UCSF Medical Center

Lisa Anne Bero, PhD


Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF


Phone: (415) 476-1067 (voice)
Box 0613, UCSF

View on UCSF Profiles


Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)

Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9; 173(22):2032-6.
    View on PubMed
  2. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013 Dec; 3(2):20405.
    View on PubMed
  3. Grundy Q, Bero L, Malone R. Interactions between Non-Physician Clinicians and Industry: A Systematic Review. PLoS Med. 2013 Nov; 10(11):e1001561.
    View on PubMed
  4. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013 Aug; 10(8):e1001500.
    View on PubMed
  5. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013 Sep; 121(9):985-92.
    View on PubMed
  6. Wolfe N, G√łtzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev. 2013; 2:31.
    View on PubMed
  7. Schroll JB, Bero L, G√łtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013; 346:f2231.
    View on PubMed
  8. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013 Apr 8; 173(7):580-1.
    View on PubMed
  9. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
    View on PubMed
  10. Conway J, Bero L, Ondari C, Wasan KM. Review of the quality of pediatric medications in developing countries. J Pharm Sci. 2013 May; 102(5):1419-33.
    View on PubMed
  11. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398.
    View on PubMed
  12. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41.
    View on PubMed
  13. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, Bero L. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012; 12:455.
    View on PubMed
  14. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12:MR000033.
    View on PubMed
  15. Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of the Cochrane library. Cochrane Database Syst Rev. 2012; 12:ED000048.
    View on PubMed
  16. Bero LA, Hill S, Habicht J, Mathiesen M, Starkopf J. The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. J Clin Epidemiol. 2013 Feb; 66(2):132-9.
    View on PubMed
  17. Bero LA, Binder L. The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. J Clin Epidemiol. 2013 May; 66(5):472-3.
    View on PubMed
  18. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012; 345:e5155.
    View on PubMed
  19. Anson A, Ramay B, de Esparza AR, Bero L. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health. 2012; 8:22.
    View on PubMed
  20. Hill S, Yang A, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012; 7(5):e38055.
    View on PubMed

Go to UCSF Profiles, powered by CTSI